Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Valeant Pharmaceuticals International, Inc.
Type
Public company
Traded as
  • NYSE: VRX
  • TSX: VRX
  • S&P/TSX 60 component
Industry Pharmaceutical industry
Founded 1960 (1960)
Headquarters Laval, Quebec, Canada
Key people
  • J. Michael Pearson (Chairman & CEO)
  • Howard B. Schiller (CFO)
Products
  • Cesamet (nabilone)
  • Efudex
  • Mestinon
  • Diastat
  • Ribavirin (licensed to Schering Plough)
  • CeraVe
Revenue Increase US$2.73 billion (Q2 2015)
Operating income
Decrease US$341.5 million (Q2 2015)
Net income
Decrease US$-56.1 million (Q2 2015)
Subsidiaries
  • Bausch & Lomb
  • Salix Pharmaceuticals
  • Medicis Pharmaceutical
  • Solta Medical
  • Dendreon
  • OraPharma
  • Obagi
Website valeant.com

Valeant Pharmaceuticals International, Inc. is a publicly traded pharmaceutical company based in Montreal, Canada. The company focuses on neurology, dermatology and infectious disease with several drugs in late-stage clinical trials and several currently on the market. In addition, Valeant has a portfolio of more than 500 products from its prior history as a group of specialty chemical and radiochemical research, development and supply companies with a history stretching back to the 1960s.

Aton Pharmaceuticals
(Acq 2010)

Vital Science Corp
(Acq 2010)

Laboratoire Dr. Renaud
(Acq 2009)

Tecnofarma
(Acq 2009)

Dow Pharmaceutical Sciences Inc
(Acq 2009)

DermaTech
(Acq 2009)

Coria Laboratories Ltd

Xcel Pharmaceuticals
(Acq 2005)

Biovail

Prestwick Pharmaceuticals
(Acq 2008)

Pharma PASS
(Acq 2002)

Fuisz Technologies Ltd
(Acq 1999)

Medicis Pharmaceutical
(Acq 2012)

Ucyclyd Pharma
(Acq 1999)

GenDerm Corporation
(Acq 1997)

PharmaSwiss S.A.
(Acq 2011)

Sanitas Group
(Acq 2011)

iNova
(Acq 2011)

Probiotica Laboratorios Ltda
(Acq 2012)

Eyetech Inc
(Acq 2012)

Pedinol
(Acq 2012)

OraPharma
(Acq 2012)

Natur Produkt
(Acq 2013)

Obagi Medical Products Inc
(Acq 2013)

Bausch & Lomb
(Acq 2013)

Solta Medical Inc
(Acq 2014)

PreCision Dermatology
(Acq 2014)

Salix Pharmaceuticals
(Acq 2015)

Dermik
(Acq 2011)

Dendreon
(Acq 2015)

Amoun Pharmaceutical
(Acq 2015)

Sprout Pharmaceuticals Inc
(Acq 2015)

Synergetics USA
(Acq 2015)

Investment goal date:
Dividends reinvested
Valeant Pharmaceuticals International, Inc. VRX report Q2 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-03-05
--
--
Q3 2017
2017-11-07
--
--
Q2 2017
2017-08-08
1.0300
-0.1100
Q1 2017
2017-05-09
0.7800
1.7900
Q4 2016
2017-02-28
1.2600
-1.4700
Q3 2016
2016-11-08
1.5500
-3.4900
Q2 2016
2016-08-09
1.4000
-0.8800
Q1 2016
2016-06-07
1.2700
-1.0800
Q4 2015
2016-03-15
2.5000
-1.1200
Q3 2015
2015-10-19
2.7400
0.1300
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
BANK OF MONTREAL /CAN/
6778655
BARCLAYS PLC
3936497
CIBC World Markets Inc.
3741413
CITADEL ADVISORS LLC
3667326
DAVIS SELECTED ADVISERS
3917812
GOLDMAN SACHS GROUP INC
7240534
Jefferies Group LLC
6346130
LMM LLC
7205675
NOMURA HOLDINGS INC
4368110
OPPENHEIMER FUNDS INC
4489169
PAULSON & CO INC
19384500
TORONTO DOMINION BANK
12034997
UBS Group AG
3426782
ValueAct Holdings, L.P.
17997224
Vanguard Group, Inc
6980074
Major Shareholders
Name Relationship
Total Shares
Holding stocks